Skip to main content

Metformin Use Tied to Lower Incidence of Death, Long COVID After COVID-19

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 19, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 19, 2024 -- After severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, prevalent metformin use is associated with a slightly lower incidence of death or postacute sequalae of SARS-CoV-2 (PASC), according to a study published online Sept. 17 in Diabetes Care.

Steven G. Johnson, Ph.D., from the University of Minnesota in Minneapolis, and colleagues conducted a retrospective cohort analysis using N3C and PCORnet electronic health record databases to examine the incidence of PASC among metformin-exposed individuals versus individuals taking other diabetes medications. PASC was defined in two ways: PASC-U09.9, which was a U09.9 diagnosis code within 180 days of the index event, and by computable phenotype in each dataset (PASC-N3C and PASC-PCORnet).

The researchers found that the hazard ratio for death or PASC-U09.9 was 0.79 (95 percent confidence interval [CI], 0.71 to 0.88), and the hazard ratio for death or PASC-N3C was 0.85 (95 percent CI, 0.78 to 0.92) in the N3C database. The hazard ratio for death or PASC-U09.9 was 0.87 (95 percent CI, 0.66 to 1.14), and the hazard ratio for death or PASC-PCORnet was 1.04 (95 percent CI, 0.97 to 1.11) in PCORnet. By diagnosis code, incident PASC was 1.6 versus 2.0 percent for metformin and comparator in the N3C, and 2.1 versus 2.5 percent in PCORnet. By computable phenotype, incidence was 4.8 and 5.2 percent for metformin and comparator in N3C, respectively, and was 24.7 versus 26.1 percent in PCORnet.

"These data support a mildly beneficial role of metformin on chronic SARS-CoV-2 outcomes in people with diabetes," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Further Support and Information on COVID-19

Read this next

Increasing Proportion of U.S. Adults Unaware They Have Hypertension

MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...

Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM

MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...

Widespread Decline Seen in MMR Vaccination Rates After COVID-19

THURSDAY, June 5, 2025 -- A widespread decrease in measles-mumps-rubella (MMR) vaccination rates was seen after the COVID-19 pandemic, according to a research letter published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.